These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17211429)

  • 1. Salvage with a mini-allograft after primary engraftment failure following autologous transplant for multiple myeloma.
    Subramaniam K; George B; Mathews V; Viswabandya A; Srivastava A; Chandy M
    Bone Marrow Transplant; 2007 Feb; 39(4):239-40. PubMed ID: 17211429
    [No Abstract]   [Full Text] [Related]  

  • 2. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
    Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D;
    Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Successful treatment with pseudo-autologous blood stem cell transplantation for an adolescent-onset multiple myeloma who relapsed after allogenic bone marrow transplantation].
    Hatsuse M; Taniguchi-Yoshihara K; Yagyu S; Fuchida S; Okano A; Murakami S; Shimazaki C
    Rinsho Ketsueki; 2015 Apr; 56(4):428-31. PubMed ID: 25971275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning.
    Zaretsky Y; Rifkind J; Lockwood G; Tsang R; Kiss T; Hasegawa W; Fyles G; Tejpar I; Loach D; Minden M; Messner H; Lipton JH
    Bone Marrow Transplant; 2007 Sep; 40(5):423-30. PubMed ID: 17603516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penicillium marneffei fungaemia in an allogeneic bone marrow transplant recipient.
    Woo PC; Lau SK; Lau CC; Chong KT; Hui WT; Wong SS; Yuen KY
    Bone Marrow Transplant; 2005 Apr; 35(8):831-3. PubMed ID: 15765113
    [No Abstract]   [Full Text] [Related]  

  • 8. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma.
    de Lavallade H; El-Cheikh J; Faucher C; Fürst S; Stoppa AM; Coso D; Bouabdallah R; Chabannon C; Gastaut JA; Blaise D; Mohty M
    Bone Marrow Transplant; 2008 Jun; 41(11):953-60. PubMed ID: 18297115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.
    Schmidt-Hieber M; Blau IW; Trenschel R; Andreesen R; Stuhler G; Einsele H; Kanz L; Keilholz U; Marinets O; Beelen DW; Fauser AA; Volin L; Ruutu T; Uharek L; Fietz T; Knauf W; Hopfenmüller W; Thiel E; Freund M; Casper J
    Bone Marrow Transplant; 2007 Apr; 39(7):389-96. PubMed ID: 17310135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allotransplantation for multiple myeloma.
    Alyea EP; Anderson KC
    Cancer J; 2001; 7(3):166-74. PubMed ID: 11419023
    [No Abstract]   [Full Text] [Related]  

  • 11. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.
    Bruno B; Sorasio R; Patriarca F; Montefusco V; Guidi S; Busca A; Scimé R; Console G; Milone G; Marotta G; Dominietto A; Giaccone L; Rotta M; Falda M; Bacigalupo A; Bosi A; Corradini P; Fanin R; Pollichieni S; Boccadoro M;
    Eur J Haematol; 2007 Apr; 78(4):330-7. PubMed ID: 17331132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
    El-Cheikh J; Michallet M; Nagler A; de Lavallade H; Nicolini FE; Shimoni A; Faucher C; Sobh M; Revesz D; Hardan I; Fürst S; Blaise D; Mohty M
    Haematologica; 2008 Mar; 93(3):455-8. PubMed ID: 18287132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow transplant and pediatric multiple myeloma.
    Davidow KA; Walter AW; Kolb EA
    Pediatr Blood Cancer; 2019 Feb; 66(2):e27528. PubMed ID: 30393949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unrelated umbilical cord blood transplantation as salvage treatment for engraftment failure following autologous stem cell transplantation.
    Fenk R; Neumann F; Fenk B; Ruf L; Zohren F; Safaian NN; Haas R; Kobbe G
    Leuk Res; 2008 Jul; 32(7):1157-9. PubMed ID: 18221996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multiple myeloma relapsed or progressed as plasmacytoma after allogeneic reduced-intensity stem cell transplantation: report of three cases].
    Sugimoto Y; Nishii K; Miyata E; Fujieda A; Yamaguchi M; Masuya M; Katayama N
    Rinsho Ketsueki; 2009 Apr; 50(4):289-94. PubMed ID: 19404022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second allogeneic transplantation using a reduced-intensity preparative regimen for relapsed myelofibrosis.
    Tanvetyanon T; Stiff PJ
    Am J Hematol; 2004 Oct; 77(2):204-5. PubMed ID: 15389913
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced.
    van Dorp S; Meijer E; van de Donk NW; Dekker AW; Nieuwenhuis K; Minnema MC; Petersen E; Schutgens R; Verdonck LF; Lokhorst HM
    Neth J Med; 2007 May; 65(5):178-84. PubMed ID: 17519513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.